Werewolf Therapeutics to Participate in the BIO International Convention

June 12, 2025

WATERTOWN, Mass., June 12, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)

June 12, 2025

Werewolf Therapeutics to Participate in the BIO International Convention

WATERTOWN, Mass., June 12, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

May 29, 2025

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

May 20, 2025

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124

WATERTOWN, Mass., May 20, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

Share this article: